IQV
IQVIA Holdings Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$266.63
−1.84%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 17.0B | 16.3B | 15.4B | 15.0B | 14.4B |
| Cost of Revenue | 12.5B | 12.0B | 10.0B | 9.7B | 9.4B |
| Gross Profit | 4.5B | 4.3B | 5.4B | 5.2B | 5.0B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 2.1B | 2.0B | 2.0B | 2.1B | 2.1B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 92.0M | — | 1.2B | 1.2B | 1.2B |
| Total Operating Expenses | 2.1B | 2.0B | 3.2B | 3.3B | 3.2B |
| Cost and Expenses | 14.7B | 14.0B | 13.2B | 13.0B | 12.6B |
| Operating Income (EBIT) | 2.3B | 2.3B | 2.2B | 2.0B | 1.8B |
| Non-Operating | |||||
| Interest Income | 37.0M | 45.0M | 47.0M | 36.0M | 13.0M |
| Interest Expense | 771.0M | 729.0M | 670.0M | 672.0M | 416.0M |
| Net Interest Income | (734.0M) | (684.0M) | (623.0M) | (636.0M) | (403.0M) |
| Other Non-Op Income/Expense | (696.0M) | (674.0M) | (533.0M) | (518.0M) | (448.0M) |
| Non-Operating Income (excl Interest) | (40.0M) | (33.0M) | (137.0M) | (154.0M) | 20.0M |
| EBT (Pre-Tax Income) | 1.6B | 1.6B | 1.7B | 1.5B | 1.4B |
| Income Tax Expense | 253.0M | 252.0M | 296.0M | 101.0M | 260.0M |
| Bottom Line | |||||
| Net Income | 1.4B | 1.4B | 1.4B | 1.4B | 1.1B |
| Earnings from Cont. Ops | 1.4B | 1.4B | 1.4B | 1.4B | 1.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.4B | 1.4B | 1.4B | 1.4B | 1.1B |
| Per Share | |||||
| Basic EPS | $8.13 | $7.91 | $7.57 | $7.39 | $5.82 |
| Diluted EPS | $8.06 | $7.84 | $7.49 | $7.29 | $5.72 |
| Revenue Per Share | $101.57 | $94.88 | $84.97 | $81.52 | $76.81 |
| Shares | |||||
| Basic Shares Outstanding | 167.2M | 171.9M | 181.3M | 183.8M | 187.6M |
| Diluted Shares Outstanding | 168.6M | 173.5M | 183.4M | 186.3M | 190.6M |
| Profitability Metrics | |||||
| EBITDA | 3.5B | 3.5B | 3.5B | 3.3B | 2.9B |
| D&A | 1.2B | 1.1B | 1.1B | 1.1B | 1.1B |
| EBIT | 2.3B | 2.3B | 2.3B | 2.1B | 1.8B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026